Universal health coverage depends on affordable medicines. But pushing down prices without also investing in quality assurance will increase the sale of substandard and falsified drugs, warns Elizabeth Pisani.
Substandard and falsified medications pose significant risks to global health. Nearly one in five antimalarials circulating in low- and middle-income countries are substandard or falsified. We assessed the health and economic impact of substandard and falsified antimalarials on children under five in Nigeria, where malaria is endemic and poor-quality medications are commonplace.
To tackle one of the most urgent public health crises facing the world today – antimicrobial resistance (AMR) – universal health coverage (UHC) must be realized. It’s time to take action by ensuring that everyone has access to safe, effective, quality-assured medicines.
This month marks the one-year anniversary of our Medicines We Can Trust campaign. To commemorate our first campaign milestone, below you’ll see a snapshot of progress over the last year, including a social media toolkit that we hope you’ll share on your channels.
Every person has the right to expect that when they use a medical product, whether medicine, vaccine or diagnostic kit, it works. But too often, that is not the case. Substandard medical products result from errors, negligence or poor practice in manufacturing, transportation and/or storage.
During this month’s United Nations General Assembly (UNGA), countries will host the first-ever High-Level Meeting on Universal Health Coverage (UHC), where they will issue a political declaration to accelerate progress toward health for all by 2030.
Quality assurance of medicines supplied to low income and middle-income countries: poor products in shiny boxes?
In today's context of globalisation of pharmaceutical production and distribution, international and national procurement agencies play a de facto key role in defining the quality of medicines available in sub-Saharan Africa.